Cambridge Innovation Capital has backed a round sized at up to $50m for disease testing kit producer Sense Biodetection, which has now raised more than $64m altogether.

UK-based infection diagnostics kit producer Sense Biodetection has secured up to $50m in commitments from investors including Cambridge Innovation Capital, the venture capital investor focused on the Cambridge, UK ecosystem. The round includes £900,000 ($1.2m) from commercialisation firm Mercia Asset Management and further participation from KDT Sense Holdings, Earlybird Health and private investors including Jonathan…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.